share_log

金斯瑞生物科技：海外監管公告-上市附屬公司傳奇生物科技股份有限公司截至二零二四年六月三十日止六個月的初步業績

GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT - PRELIMINARY RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION

Hong Kong Stock Exchange ·  Jul 26 19:32
Summary by Futu AI
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）旗下非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」），於2024年7月26日公佈了截至2024年6月30日止六個月的初步未經審核財務業績。該業績顯示，傳奇生物預期錄得經調整淨虧損約94.7百萬美元至109.7百萬美元。這份初步業績是根據當前可用資料的估計，並將於2024年8月9日提供完整的財務報告。傳奇生物是一家致力於開發細胞療法的全球生物技術公司，其股份以美國存託股份形式於美國納斯達克全球精選市場上市。公司強調，由於財務結算程序尚未完成，最終業績可能與初步估計有所不同，並提醒投資者注意投資風險。
金斯瑞生物科技股份有限公司（「金斯瑞生物科技」）旗下非全資附屬公司傳奇生物科技股份有限公司（「傳奇生物」），於2024年7月26日公佈了截至2024年6月30日止六個月的初步未經審核財務業績。該業績顯示，傳奇生物預期錄得經調整淨虧損約94.7百萬美元至109.7百萬美元。這份初步業績是根據當前可用資料的估計，並將於2024年8月9日提供完整的財務報告。傳奇生物是一家致力於開發細胞療法的全球生物技術公司，其股份以美國存託股份形式於美國納斯達克全球精選市場上市。公司強調，由於財務結算程序尚未完成，最終業績可能與初步估計有所不同，並提醒投資者注意投資風險。
Genscript Bio, a non-wholly-owned subsidiary of Genscript Biotech, announced its unaudited financial performance for the first six months ending on June 30, 2024 on July 26, 2024.In that period, Legend Biotech is expected to record an adjusted net loss of $94.7 million to $109.7 million. This preliminary performance is estimated based on the available data and will provide a full financial report on August 9, 2024. Legend Biotech is a global biotechnology company dedicated to developing cell therapies, whose shares are listed on the Nasdaq Global Select Market in the United States. The company emphasized that the final performance may differ from the preliminary estimate because the financial settlement process is not yet completed and reminded investors to pay attention to investment risks.
Genscript Bio, a non-wholly-owned subsidiary of Genscript Biotech, announced its unaudited financial performance for the first six months ending on June 30, 2024 on July 26, 2024.In that period, Legend Biotech is expected to record an adjusted net loss of $94.7 million to $109.7 million. This preliminary performance is estimated based on the available data and will provide a full financial report on August 9, 2024. Legend Biotech is a global biotechnology company dedicated to developing cell therapies, whose shares are listed on the Nasdaq Global Select Market in the United States. The company emphasized that the final performance may differ from the preliminary estimate because the financial settlement process is not yet completed and reminded investors to pay attention to investment risks.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.